Multiple Myeloma

MULTIPLE MYELOMA NEWS TIPS & FEATURES

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring […]


Darzalex® Approved for Additional Indications in Multiple Myeloma

November 29th, 2016

Darzalex® Approved for Additional Indications in Multiple Myeloma

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least […]


HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

October 12th, 2016

HOVON Trial: Autologous Stem Cell Transplant Remains Superior to Novel Agents for Treatment of Multiple Myeloma

A large, comparative, phase III HOVON clinical trial recently confirmed that upfront autologous stem cell transplantation (ASCT) should still be the treatment of choice in […]


Advances offer Promise for Multiple Myeloma Patients

September 1st, 2016

Advances offer Promise for Multiple Myeloma Patients

With a growing number of treatment options, the out­look is improving for patients with this blood cancer. By Mia James Una Wilson initially thought that […]


Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma

July 7th, 2016

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were […]


Ask the Expert: Multiple Myeloma

May 4th, 2016

Ask the Expert: Multiple Myeloma

CancerConnect recently collaborated with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to provide you […]


Aplidin® Improves Progression-Free Survival in Multiple Myeloma

April 21st, 2016

Aplidin® Improves Progression-Free Survival in Multiple Myeloma

The addition of the investigative agent Aplidin® (plitidepsin) to dexamethasone appears to significantly reduce the risk of cancer progression or death compared to dexamethasone alone […]


Have a Question about Multiple Myeloma? Join us on April 28th

March 30th, 2016

Have a Question about Multiple Myeloma? Join us on April 28th

CancerConnect and The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute Will Present: Ask the Expert with Dr. Hofmeister CancerConnect […]


Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant

March 30th, 2016

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell […]


Farydak® Significantly Improves Outcomes for Heavily Pre-Treated Multiple Myeloma

March 10th, 2016

Farydak® Significantly Improves Outcomes for Heavily Pre-Treated Multiple Myeloma

The addition of Farydak® (panobinostat) to the standard treatment combination consisting of Velcade® (bortezomib) and dexamethasone significantly improves progression-free survival among patients with advanced multiple […]


More News →